Biopharma Talent Hunt: Top C-suite Recruiter Mulls The Next Generation Of Leaders
An interview with Odgers Berndtson's John Hawkins about the credentials needed for the next-gen biopharma C-suite. A supplement to our feature on the In Vivo/EBD Academy survey, “Future-Proofing Human Capital: Does Biopharma Have the Right Stuff?”
You may also be interested in...
Takeda’s Take On The Future Of Biopharma Human Capital
In this supplement to our feature on the In Vivo/EBD Academy survey "Future-Proofing Human Capital In Global Life Sciences", Ramona Sequeira, President of Takeda Pharmaceutical's US Business Unit, presents her company’s strategy to anticipate and respond to a disruptive transformation of the industry payer base.
Future-Proofing Human Capital: Does Biopharma Have The Right Stuff?
Biopharma's future depends entirely on the application of human ingenuity to complex problems with no easy solutions. In Vivo, with its Informa business solutions partner EBD Academy, recently conducted a survey of industry decision-makers in the US and Europe for recommendations on how to attract talent, boost employee engagement, foster diversity and maintain the product innovation that patients demand and society expects.
Viz.ai: Precision Targeting Of Every Patient’s Medical “Moment Of Truth”
Viz.ai is making artificial intelligence real and ready with an algorithm-based detection and diagnostics platform that is beating the clinical clock in fighting stroke. The start-up is now focused on positioning its joined-up AI software as standard-setter for broader patient engagement with big pharma on everything from participation in clinical trials to launching the next generation of high-touch specialty medicines.